Disposal Group, Including Discontinued Operation, Consideration, Market Value

No definition available.

Name:	mdco_DisposalGroupIncludingDiscontinuedOperationConsiderationMarketValue
Namespace Prefix:	mdco_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Disposal Group, Including Discontinued Operation, Consideration, Shares

+ References

No definition available.

+ Details

Name:	mdco_DisposalGroupIncludingDiscontinuedOperationConsiderationShares
Namespace Prefix:	mdco_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Disposal Group, Including Discontinued Operation, Receivable Due in 12 Months

+ References

No definition available.

+ Details

Name:	mdco_DisposalGroupIncludingDiscontinuedOperationReceivableDuein12Months
Namespace Prefix:	mdco_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Disposal Group, Including Discontinued Operation, Receivable Due in 18 Months

+ References

No definition available.

+ Details

Name:	mdco_DisposalGroupIncludingDiscontinuedOperationReceivableDuein18Months
Namespace Prefix:	mdco_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Disposal Group, Including Discontinued Operation, Tiered Royalty Payments, Percent Of Net Sales

+ References

No definition available.

+ Details

Name:	mdco_DisposalGroupIncludingDiscontinuedOperationTieredRoyaltyPaymentsPercentOfNetSales
Namespace Prefix:	mdco_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Proceeds From Divestiture Of Businesses, Contingent Consideration

+ References

No definition available.

+ Details

Name:	mdco_ProceedsFromDivestitureOfBusinessesContingentConsideration
Namespace Prefix:	mdco_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Proceeds From Divestiture Of Businesses, Upfront Consideration Received

+ References

No definition available.

+ Details

Name:	mdco_ProceedsFromDivestitureOfBusinessesUpfrontConsiderationReceived
Namespace Prefix:	mdco_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.

+ References

No definition available.

+ Details

Name:	us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_ShortTermInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdco_InfectiousDiseaseBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mdco_SandozIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mdco_AngiomaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mdco_OpexBiopharmaInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mdco_MelintaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Nature of Business (Details) - USD ($)			1 Months Ended		9 Months Ended
Nature of Business (Details) - USD ($)	Oct. 02, 2018	Jan. 05, 2018	Oct. 31, 2018	Aug. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Short-term investment					$ 13,089,000		$ 0
Proceeds from sale of business					166,383,000	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Infectious Disease Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total sale price		$ 166,400,000
Consideration received (in shares)		3,313,702
Consideration received, market value		$ 54,500,000
Receivable due in 12 months		25,000,000
Receivable due in 18 months		$ 25,000,000
Proceeds from sale of business					166,383,000	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Infectious Disease Business \| Minimum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Tiered royalty payments, percent of net sales		5.00%
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Infectious Disease Business \| Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Tiered royalty payments, percent of net sales		25.00%
Sandoz Inc \| Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Angiomax
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business				$ 9,900,000
Subsequent Event \| Opex Biopharma, Inc. \| Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Infectious Disease Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront consideration received	$ 2,700,000		$ 2,700,000
Contingent consideration	$ 29,000,000		$ 29,000,000
Melinta
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Short-term investment					$ 13,100,000